If You Invested in BNB Plus Corp (BNBX)

BNB Plus Corp. (Nasdaq: BNBX) is a company that combines a digital asset treasury strategy centered on the BNB token with the commercialization of nucleic acid production technologies for biopharmaceutical and diagnostics applications. According to its public disclosures and recent press releases, the company is focused on a yield-oriented BNB digital asset treasury while continuing to develop and supply its proprietary LineaDNA platform through its LineaRx, Inc. subsidiary.

Business Focus and Strategy

BNB Plus describes its core financial strategy as unlocking institutional-grade access to the Binance ecosystem. The company states that it delivers non-directional yield strategies and long BNB exposure through a transparent, actively managed BNB treasury. Its stated approach blends decentralized finance (DeFi) yield generation with Binance-native opportunities, with the goal of providing access to high-performance digital assets for investors that have historically been excluded from this area.

In multiple press releases, the company characterizes BNB as a foundational strategic asset and outlines a disciplined accumulation strategy aligned with long-term value objectives. BNB Plus has also launched a digital asset dashboard (BNBX.io) that it describes as providing real-time portfolio metrics for its BNB treasury holdings, key valuation metrics, and capitalization details, intended as a supplemental information source alongside SEC filings.

LineaDNA Platform and Life Sciences Activities

Alongside its digital asset treasury activities, BNB Plus continues to operate in the biotechnology and diagnostics space through its LineaRx subsidiary. The company reports that LineaRx is commercializing the LineaDNA platform, which it describes as a proprietary, cell-free DNA production system leveraging expertise in large-scale PCR. According to company disclosures, the LineaDNA platform is designed to produce high-fidelity DNA that is free of adventitious sequences, rapidly scalable, and amenable to chemical modification.

BNB Plus states that LineaDNA can generate DNA from 100 base pairs to 20 kilobases in quantities ranging from milligrams to grams, under research use only (RUO), good laboratory practice (GLP), and good manufacturing practice (GMP) quality grades. The company reports that LineaDNA is used as a functional component in cancer diagnostic tests and is supplied to customers in the in vitro diagnostics (IVD) and biotherapeutic markets under supply agreements.

Customer and Market Activity

Recent news releases highlight multi-year and multi-gram LineaDNA supply relationships. BNB Plus has disclosed a significant order from a global manufacturer of in vitro diagnostics under an existing supply agreement, including an accelerated LineaDNA order that consolidated a two-year purchasing cycle into a shorter delivery window. The company has also reported the successful manufacture and shipment of what it describes as the largest single LineaDNA order in its history, delivered under a supply agreement for cancer diagnostic use.

These disclosures indicate that BNB Plus’s life sciences operations are oriented toward supplying DNA materials for diagnostic and biotherapeutic applications, while its corporate strategy also emphasizes the development of a BNB-based digital asset treasury.

Corporate Evolution and Identity

BNB Plus Corp. is the new corporate name of the entity formerly known as Applied DNA Sciences, Inc. The company has stated that the rebrand is aligned with its yield-focused BNB treasury strategy and its BNBX ticker symbol. Public communications describe this as a transition in which the company maintains its nucleic acid production activities while adding a digital asset treasury mandate built around BNB and the Binance ecosystem.

The company has also reported the launch of a new corporate website and updated branding that it says reflect a dual mandate: operating in biotechnology segments through nucleic acid production and acting as a corporate holder and beneficiary of the BNB token and related Binance-native opportunities.

Capital Markets and Regulatory Status

BNB Plus Corp.’s common stock is listed on The Nasdaq Capital Market under the symbol BNBX, as confirmed in its SEC filings. In an S-1/A registration statement, the company identifies itself as a smaller reporting company and outlines the registration of shares associated with private placements, warrants, and advisory arrangements. The filing describes a cash private placement and a crypto private placement, along with related pre-funded warrants and Series E warrants, and explains that the registration is for resale by selling stockholders.

The company has also disclosed the closing of a private placement intended to support its BNB treasury strategy, involving cash, stablecoins, and units of an OBNB trust that provide exposure to BNB tokens. According to its disclosures, BNB Plus intends to use net proceeds from such financings to implement its treasury strategy, support working capital, and address transaction-related expenses.

Governance and Shareholder Actions

In an 8-K filing describing a special meeting of stockholders, BNB Plus reported shareholder approval of several proposals, including the exercisability of certain pre-funded warrants and common stock purchase warrants issued under a securities purchase agreement, an increase in authorized shares of common stock, and an increase in shares reserved under the company’s equity incentive plan. These actions, as described in the filing, are related to the company’s capital structure and its ability to issue additional equity-linked securities.

The company has also publicly announced board-level changes in connection with its rebranding, including the election of a new chairman of the board, which it characterizes as supportive of its DeFi-focused leadership and digital asset strategy.

Business Model Overview

Based on its public statements, BNB Plus’s business model has two primary components:

• Digital Asset Treasury Strategy: A BNB-focused treasury that seeks non-directional yield and long BNB exposure through a transparent, actively managed approach that incorporates DeFi and Binance-native opportunities.
• Nucleic Acid Production: Commercialization of proprietary nucleic acid production technologies, particularly the LineaDNA platform, for use in biopharmaceutical and diagnostics markets, including supply agreements for cancer diagnostic and IVD applications.

The company’s disclosures position these activities as complementary, with the biotechnology operations providing an operating business alongside the digital asset treasury.

Frequently Asked Questions